Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at TD Cowen.
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $192.00 price target on the stock.
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $192.00 price target on the stock.